OncoResponse raises $40M Series B to target immunotherapy ‘elite responders’
The company aims to develop therapeutics focused on antibodies found in patients who respond well to cancer immunotherapies and develop treatments for those who do not.
Precision BioSciences’ $1.6B Baxalta deal could make CAR-T allogeneic
Making CAR-T therapeutics allogeneic would significantly improve its scalability - but it's been a tough goal to conceive. Precision BioSciences' genome editing deal with Baxalta could make it a reality.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Morning Read: Full Baxalta-Shire repercussions, a higher-bar for Aetna and Cigna mergers
Also, learn how consumers are gaming Obamacare, the next moves to get better reimbursement for telemedicine, and meet some impressive new venture partners.
Morning Read: Baxalta-Shire isn’t slowing down, biotech IPOs speed up and about those wearables
Also, Withings unveils a smart thermometer at CES, BIO changes its name, and a new British-backed sugar-measuring smartphone app.
Morning Read: Shire coming back at Baxalta, more reasons to ogle Google in healthcare
Plus, another life science IPO in London, a shifting (and slowing) of Obamacare dollars and much more
Morning Read: Shire made a $30B offer to acquire biopharma company Baxalta, patient readmission costs have added up to $420M
Rare disease specialist Shire has made a $30B offer to acquire biopharma company Baxalta, and patient readmission costs have added up to $420M resulting in penalties against hospitals.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.